

DAFTAR PUSTAKA

1. Carter E, Barr S, Clarke A. The global burden of SLE : prevalence, health disparities and socioeconomic impact. *Nat Rev Rheumatol*. 2016;12(10):1—6.
2. Bertias G, Cervera R, Boumpas D. Systemic lupus erythematosus : pathogenesis and clinical features. *EULAR*. 2012; 476—505.
3. Chavele K, Ehrenstein M. Regulatory T-cells in SLE and rheumatoid arthritis. *FEBS*. 2011;585: 3603—10
4. Araujo JA, Mesquita D, Cruvinel W, Salmazi K, Kallas EG, Andrade LE. Th17 Cells and CD4+ Multifunctional T cells in patients with systemic lupus erythematosus. *Rev Bras Reumatol*. 2016;56: 28—36.
5. Sonawale A, Bohara V, Bichile L. Evaluation of the association between CD4, CD8, CD25 cell counts and SLE in active disease and in remisson. *Journal of the Association of Physicians of India*. 2017; 65: 37—42
6. Ohl K, Tenbrock K. Regulatory T cells in systemic lupus erythematosus. *Eur J Immunol*. 2015; 45: 344—55
7. Humrich J, Morbach H, Undeutsch R, Enghard P, Rosenberger P , Weigert S, et al. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. *Proc Natl Acad Sci*. 2010; 107:204—09
8. Martin g, Zamudio D, Vanoye G, Crispin J, Varela A. Quantitative and functional profiles of CD4+ lymphocyte subsets in systemic lupus erythematosus patients with lymphopenia. *Clinical and Experimental Immunology*. 2011; 164: 17—25.
9. Ma L, Zhao P, Jiang Z, Shan Y, Jiang Y. Imbalance of different types of CD4+FOXP3+ T cells in patients with new-onset systemic lupus erythematosus. *Clinical and experimental immunology*. 2013; 174: 345—55.
10. Kalim H, Handono K, Hasanah D. Hubungan kadar vitamin D dengan jumlah sel T regulator pada pasien lupus eritematosus sistemik. *Research Journal of Life Science*. 2015; 2: 1—6.
11. Sadlack B, Lohler J , Schorle H. Generalized autoimmune disease in IL-2 deficient mice is triggered by uncontrolled activation and proliferation CD4+ T cells. *Eur J immunol*. 1995; 25: 3053—59.

12. Sedighi s, Aghaei M, Musavi S, Nomali M. Relationship between serum level of IL-2 in patients with systemic lupus erythematosus and disease activity in comparison with Control Group. 2014;1—4.
13. Chen Q, Kim YC, Laurence A, Punkosdy GA, Shevach EM. Interleukin-2 controls the stability of FOXP3 expression in TGF beta induced FOXP3 T cells in vivo. *J Immunol.* 2011; 186: 6329—37.
14. Lieberman L, Tsokos G. The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on Host immunity. *journal of Biomedicine and biotechnology.* 2010;1—6.
15. Tsokos G, Lo MS, Reis PC, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. *Nat. rev.* 2016; 12: 716—30.
16. Sinha A, Bagga A. Pulse steroid therapy. *Indian J Pediatr.* 2008; 75:1057—66.
17. Perhimpunan Reumatologi Indonesia.Rekomendasi diagnosis dan pengelolaan lupus eritematosus sistemik.2011;10—15
18. Parker B, Bruce I. High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. *Lupus.* 2007; 16: 387—93.
19. Theresea Magbitang, Rubio AK, Salido E. In-Hospital outcomes of methylprednisolone pulse therapy in the treatment of systemic lupus erythematosus. *Philip. Journ. of Internal Medicine.* 2014; 52: 1—7.
20. Mathian A, Jounne R, Chader D, Cohen-aubart F, Haroche J, Fadlallah J, et al. Regulatory T cell responses to high-dose methylprednisolone in Active systemic lupus erythematosus. *PLoS ONE.* 2015; 10: 1—17.
21. Kaul A, Gordon C, Crow , Touma Z, Urowitz M, Vollenhoven R, et al. Systemic lupus erythematosus. *Nat. Rev.* 2016; 2: 1—21.
22. Choi J, Kim S, Craft J. The Pathogenesis of systemic Lupus Erythematosus update. *Curr.Opin.Immunol.* 2012; 24(6): 651—57.
23. Celhar T, Fairhurst A. Modelling clinical systemic lupus erythematosus similarities,differences, and success stories. *Rheumatology.*2017;56: 188—99.
24. Ronnblom L, Pascual V. The innate immune system in SLE : type I interferons and dendritic cells. *Lupus.* 2008; 17(5): 394—399.

25. Liu Z, Davidson A. Taming lupus- an new understanding of pathogenesis is leading to clinical advange. *Nat. Med.*2012; 18: 476—505.
26. Ganguly D, Haak S, Sisirak V, Reizis B. The role of dendritic cells in autoimmunity. *Nat. Rev. Immunolog.* 2013;1—12.
27. Ines L, Silvia C, Galindo M, Lopez-longo F, Terroso G, Romao V, et al. Classification of systemic lupus erythematosus: systemic lupus international collaborating clinics versus american college of rheumatology criteria. A comperative study of 2055 patients from a real-life, international systemic lupus erythematosus cohort. *Arthritis Care&research.* 2015; 67: 1180—1185.
28. Okamoto A, Fujio K, Okamura T, Yamamoto K. Regulatory T cell associated cytokines in systemic lupus erythematosus. *Journal of biomedicine and bio technology.* 2011;1—9.
29. Comte D, Karampetsou MP, Tsokos GC. T cells as Therapeutic target in SLE. *Lupus.* 2015; 24—30
30. Mak A, Kow N. The pathology of T cells in systemic lupus erythematosus. *J. Immunol.Res.* 2014;1—9.
31. Perl A. Oxidative stress in the pathology and treatment of systemic lupus erythematosus. *nat. Rev. Rheumatol.* 2013;1—13.
32. Apostolidis SA, Crispin JC, Tsokos G. IL-17 producing T cells in systemic lupus nephritis. *Lupus.* 2011; 20: 120—124.
33. Josefowicz SZ, Lu LF, Rudensky A. Regulatory T cells : Mechanism of differentiation and function. *Annu. Rev. Immunol.* 2012; 30: 531—64.
34. Tselios K, Sarantopoulos A, Gkoukourelias I, Boura P. T Regulatory cells in systemic lupus erythematosus : Current knowledge and future prospects. *Intech.* 2017;124—53.
35. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells : How do they suppress immune responses? *International immunology.* 2009; 21: 1105—11.
36. Moulton V.R. Sex hormones in acquired immunity and autoimmune disease. *Front Immunol.*2018;9:1—21
37. Colasanti T, Maselli A, Conti F, Sanchez M, Alessandri C, Barbati C, et al. Autoantibodies to estrogen receptor α interfere with T lymphocytehomeostasis and are associated with disease activity in systemic lupus erythematosus. *Arthritis Rheum.*2012.64;778—87

38. Apostolidis S, Lieberman L, Kis-Toth K, Crispin J, Tsokos G. The dysregulation of cytokine networks in systemic lupus erythematosus. *Journal of interferon and cytokine research*.2011;31;1—12
39. Kleiner G, Marcuzzi A, Zanin V, Monasta L, Zauli G. Cytokine levels in the serum of healthy Subjects. *Mediator of Inflammation*. 2013; 1—6.
40. Boyman O, Sprent J. The role of IL-2 during homeostasis and activation of the immune system. *nature.Rev.immunol*. 2012; 12: 180—90.
42. Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. *Nature.Rev.Immunol*. 2015; 1—12.
43. Mizui M, Tsokos G. Low dose IL-2 as a regulatory immunotherapy for systemic lupus erythematosus. *J Xiangya Med*. 2016;1—5.
44. Humrich J, von Spee-Mayer C, Siegert E. Rapid induction of clinical remission by low dose IL-2 in patient with refractory SLE. *Ann Rheum Dis*. 2015; 74: 791—2.
45. Cain DW, Cidiowski J. Immune regulation by glucocorticoid. *Nat Rev Immunol*. 2017; 1—15.
46. Zhou XJ, Cheng FJ, Zhang H. Emerging View of Autophagy in Systemic Lupus Erythematosus. *Int Rev Immunol*. 2014; 1—13.
47. Ohkura N, Kitagawa Y, Sakaguchi S. Development and maintenance of regulatory T cells. *Immunity*. 2013; 8: 665—80.
48. Harr M, McColl K, Zhong F. Glucocorticoid downregulate Fyn and inhibit calcium signaling to promote autophagy in T lymphocytes. *Autophagy*. 2010; 6: 912—26.
49. Badsha H, Edwards CJ. Intravenous pulses of methylprednisolone for systemic lupus erythematosus. *Semin Arthritis rheum*. 2003; 32: 370—77.
50. Webel M, Ritts R, Taswell H, Danadio J. cellular immunity after intravenous administration of methylprednisolone. *J Lab Clin Med*. 1974; 83: 383—92.
51. Badsha H, Lian T, Chan S, Edwards C, Chng H. Low dose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications. *Lupus*. 2002; 11: 508—13.
52. Hashimoto H. Glucocorticoid Therapy in SLE-Clinical Analysis of 1125 patients with SLE. *Glucocorticoids*. 2012;481—500.

53. Tsujimura S, Adachi T, Saito K, Tanaka Y. Role of P-glycoprotein on CD69+ CD4+ cells in the pathogenesis of proliferative lupus nephritis and non-responsiveness to immunosuppressive therapy. *RMD open*.2017;3:1—9
54. Jung Ju-yang, Suh Chang-Hee. Infection in systemic lupus erythematosus, similarities and differences with lupus flare. *Korean J Intern Med*.2017;32: 429— 34
55. Migita K, Sasaki Y, Ishizuka N, Arai T, Kiyokawa T, Suematsu E. Glucocorticoid therapy and the risk of infection in Patient with newly diagnosed autoimmune disease. *medicine*. 2013; 92: 285—93.
56. Beca S, Rodriguez-Pinto, Alba MA, Cervera R, Espinosa G. Development and validation of a risk calculator to differentiate flares from infections in SLE patients with fever. *Autoimmun Rev*.2015;14:586—93.
57. Zanana-nacach A, Bar S.G, Magder L.S, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. *Arthritis Rheum*.2000; 5:1—8
58. Jongen P.J, Stavrakaki I, Voet B, Hoogervost E, Munster E.V, et al. Patient reported adverse effects of high-dose intravenous methylprednisolone treatment : a prospective web-based multi center study in multiple sclerosis patients with relapse. *J Neurol*.2016;263:1641—51
59. Khan D, Ahmed S.A. The Immune system is a natural target for estrogen action : opposing effects of estrogen in two prototypical autoimmune disease. *Front Immunol*.2015;6:1—8
60. Kanda N, Tamaki K. Estrogen enhances immunoglobulin production by human PBMCs. *J Allergy Clin Immunol*.1999;103:282—8
61. Venkatesh J, Yoshifuji H, Kawabata D, Chinnasamy P, Stanevsky A, Grimaldi CM, et al. Antigen is required for maturation and activation of pathogenic anti-DNA antibodies and systemic inflammation. *J Immunol*. 2011; 186: 5304—12.
62. Tai P, Wang J, Jin H, Song X, Yan J, Kang Y, et al. Induction of regulatory T cells by physiological level estrogen. *J Cell Physiol*.2008;214:456—64.

63. Hill L, Jeganathan V, Chinnasamy P, Grimaldi C, Diamond B. Differential roles of estrogen receptors alpha and beta in control B-cell maturation and selection. *Mol Med*.2011;17:211—20
64. Jakes W.R, Bae S.C, Louthrenoo W, Mok C.C, Navarra S.V, Kwon N. Systemic review of the epidemiology of systemic lupus erythematosus in Asia Pacific region :prevalence, incidence, clinical features, and mortality. *American College of rheumatol*. 2012;64:159—68.
65. Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus : a systemic review of epidemiological studies. *Rheumatology*. 2017;56:1945—61.
66. Fabrizio C, Fulvia C, Carlo P, Laura M, Elisa M, Francesca M. Systemic lupus erythematosus with and without Anti-dsDNA antibodies : Analysis from a large monocentric cohort. *Mediator of inflammation*.2015.1—14
- 67 Ferreira S, Vasconcelos J, Marinho A, Farinha F, Almeida I, Correia J, et al. Limfopenia T CD4 in lupus erythematosus sistemic. *Acta reumatol port*.2009; 34:200—6.
- 68 Baharuddin H, Zainudin N, Ahmad A, Rosman A, Zain M.M. CD4 and CD8 count in patients with systemic lupus erythematosus-associations with infection and disease activity. *Annals of Rheumatology Journals*.2017;76:1—4
- 69 Wu Lifan, Wang X, Chen F, Lv X, Sun W, Guo Y, et al. T cell subsets and immunoglobulin G levels are associated with the infection status of systemic lupus erythematosus patients. *Braz J Med Biol Res*.2018;51: 1—7.
- 70 Rasmussen T, Bak R, Andersen T, Dige A, Holm C, Mikkelsen J. MicroRNA-21 can regulate apoptosis of CD4+T cells in SLE. *Rheumatology*.2015;38:603-13.
- 71 Mizui M, Tsokos G.C. Targeting regulatory T cells to treat patients with Systemic lupus erythematosus. *Front immunol*.2018;9:786—96
72. Yang X, Sun B, Wang H, Yin C, Wang X, Ji X. Increased serum IL-10 in lupus patients promotes apoptosis of T cell subsets via the caspase 8 pathway initiated by Fas signaling. *The Journal of Biomed Research*.2015;29:232—40

73. Bonelli M, Savitskaya A, Steiner CW, Rath E, Smolen JS, Scheinecker C. Phenotypic and functional analysis of CD4⁺CD25⁺FOXP3⁺ T cells in patients with systemic lupus erythematosus. *J Immunol*.2009;182:1688—95
74. Suen J.L, Chiang B.L. CD4⁺FOXP3⁺ regulatory T cells in human systemic lupus erythematosus. *Journal of the Formosan Medical Association*.2012 ;111: 465—70
75. Kosmaczewska A, Ciszak L, Sztęblich A, Wiland P. Peripheral blood Th17/Treg imbalance in patients with low –active systemic lupus erythematosus.
76. Tselios K, Sarantopoulos A, Gkougkourelas I, Boura P. The influence of therapy on CD4⁺CD25^{high}FOXP3⁺ regulatory T cells in systemic lupus erythematosus patients : a prospective study. *Scand J Rheumatol*.2015;44: 29—35.
77. Olnes MJ, Kotliarov Y, Biancotto A, Cheung F, Chen J, Shi R. Effects of systemically administered hydrocortisone on the human immunome. *Scientific report*.2016;6:1—16
78. Sbiera S, Dexneit T, Reichardt S.D, Michel K.D, Brandt J, Schull S, et al. Influence of short-term glucocorticoid therapy on regulatory T cells *in vivo*. *PLoS ONE*.2011;6:1—10
79. Gao H, Wang Q, Yu X, Liu J, Bai S, Feng J, et al. Molecular mechanism of glucocorticoid resistance in systemic lupus erythematosus: A review. *Life Sciences*.2018;209:383—87
80. Ugor E, Prenek L, Pap R, Berta G, Emzt D, Najbauer J, et al. Glucocorticoid hormone treatment enhances the cytokine production of regulatory T cells by upregulation of FOXP3 expression. *Immunobiology*.2018;223:422—31
81. Yamagouchi J, Rainbow D, Serra P, Howlett S, Hunter K, Garner VE, et al. Interleukin 2 gene variation impairs regulatory T cell function and causes autoimmunity: *Nat Genet*.2007;39:857—64
82. Moon B.I, Kim T.H, Seoh J.Y. Functional modulation of regulatory T cells by IL-2. *PLoS ONE*.2015;10:1—12
83. Jainuri E.P, Arofa I, Bagus PP, Yulistiani. Megadose methylprednisolone on total lymphocyte count and disease activity in systemic lupus erythematosus. *Folia medica indonesiana*.2015;51:40—4